Advertisement
The founding members of the Consortium include the Foundation for theNational Institutes of Health (FNIH), National Institutes of Health (NIH),Food and Drug Administration (FDA), Centers for Medicare & Medicaid Services(CMS); and the Pharmaceutical Research and Manufacturers of America (PhRMA).
Advertisement
"We are pleased to join the Biomarkers Consortium and to have theopportunity to participate in an evolving dialog with key thought leaders fromtop research organizations and agencies world-wide," stated Art Okamoto,Senior Product Manager at Ingenuity. "We are excited about the prospectsoffered by the Biomarkers Consortium, and hope to contribute to thedevelopment and accessibility of biomarker research in the scientificcommunity."
Ingenuity is committed to helping life science researchers generatemaximum value from all types of biological and chemical knowledge. Ingenuityhas recently launched IPA-Biomarker(TM) to help researchers identify andprioritize biomarker candidates based on key biological characteristics.Ingenuity's technology supports the Consortium's goal of advancing biomarkerresearch by linking potential markers to a disease or biological process ofinterest.
About Ingenuity Systems(R)
Ingenuity Systems enables researchers to model, analyze, and understandcomplex biological and chemical systems foundational to human health anddisease. All of Ingenuity's products and services have one common goal -- toprovide relevant context and understanding to life science researchers. TheIngenuity products include pathways analysis software and knowledge bases forlife scientists and bioinformaticians, in addition to business solutionsfocused on semantic search and enterprise knowledge management infrastructure.Ingenuity was founded in 1998 and is headquartered in Redwood City, Californiawith offices in Germany, Switzerland, France, the United Kingdom, and Japan.http://www.ingenuity.com.
SOURCE Ingenuity Systems
